logo
What to know about GLP-1 supplements for weight loss

What to know about GLP-1 supplements for weight loss

Yahoo22-04-2025
As the Food and Drug Administration cracks down on compounded versions of popular weight loss drugs Wegovy (semaglutide) and Zepbound (tirzepatide), Americans who rely on these cheaper medications may be drawn to a dicey sector of the dietary supplement market.
From colorful patches and fruit punch-flavored gummies to prebiotic powders and under-the-tongue tinctures, dietary supplements that claim to 'complement' or 'supercharge' the body's levels of the gut hormone GLP-1 are a dime a dozen. While compounded drugs require at least a virtual consultation with a clinician to get a prescription, supplements are available over the counter.
At best, such products are misleading, said Jamie Alan, an associate professor of pharmacology and toxicology at Michigan State University's College of Human Medicine. So-called GLP-1 supplements, named to echo the class of glucagon-like peptide-1 agonist drugs that includes Wegovy and Zepbound, are likely to be ineffective for weight loss.
'If you can buy it without a prescription, it's not an actual GLP-1 drug,' Alan said. 'It is something else that's marketed to support your endogenous GLP-1 production. These things are just older weight loss [supplements] that are rebranded, and there's really no scientific evidence for these.'
Ashwagandha and green tea extract are among the natural ingredients that have been recycled in diet products for decades, Alan said. Ashwagandha is often advertised as a stress reliever, and though the stress hormone cortisol is tied to weight gain, there's little proof the evergreen shrub directly helps shed pounds. Green tea and green tea extract may have a 'possible modest effect on body weight,' according to mixed research cited by the Office of Dietary Supplements, some of which links the extract to liver damage.
'We're coming back to these products that have been ineffective in the past,' Alan said. Ingredients popping up on GLP-1 supplement labels include everything from berberine to chromium to saffron extract, which have a minimal body of research supporting their effects on weight loss.
What's missing from the ingredient lists is also of note.
The brand Kind Patches indicates its GLP-1 adhesive 'does not contain synthetic GLP-1 and is not a GLP-1 agonist drug.' Lemme, Kourtney Kardashian Barker's wellness brand, features an identical disclaimer for its GLP-1 Daily Support Capsules. Trim Biome GLP-1, manufactured by Inno Supps, boasts 'clinically studied ingredients' but not the hormone in the product's name.
Lemme declined to comment; Inno Supps and Kind Patches didn't respond to a request for comment.
Jeff Ventura, the vice president of communications for the Council for Responsible Nutrition, a trade group for the supplement industry, said in a statement that there are 'no direct comparators' for GLP-1 drugs in the dietary supplement industry.
'While some supplement ingredients have shown promise in limited studies related to metabolic health and weight management, they do not have the same effects as GLP-1 drugs,' Ventura said.
'It is very tricky, because they'll put that big 'GLP-1' on there and it makes you think, 'Well, maybe this is the drug,' if you're not thinking about how to read these labels or if you don't know how to read these labels,' Alan said.
The FDA doesn't regulate dietary supplements for safety or effectiveness before they hit the market, whether they're a daily multivitamin or a post-workout protein powder. For that reason, the agency advises consulting a health care provider before adding any supplement to your regimen.
'There could be harm in some of these,' Alan said. 'There are going to be some people who might have a significant drug interaction, who might have a significant medical condition. In most people there's probably minimal risk of harm, but that's not true for everyone.'
GLP-1 drugs aren't new, having been used to treat Type 2 diabetes since 2005. Demand soared after the FDA approved Wegovy and Zepbound for weight loss in 2021 and 2023, respectively. The ensuing shortages made it legal for compounding pharmacies to step in.
Compounding pharmacies typically mix, alter or combine drug ingredients to meet a patient's specific needs. For example, a pharmacy may make a liquid version of a drug that only comes in pill form for a patient who has trouble swallowing. During drug shortages, they're also authorized to craft medications that are 'essentially copies' of commercially available drugs.
Compounded versions of Wegovy and Zepbound skyrocketed in popularity — in part because they were generally sold for far less than their brand-name counterparts. Wegovy, for instance, has a list price of $1,349.02 for a four-week supply, though some insurance plans cover it. Meanwhile, WeightWatchers offers compounded semaglutide starting at $129 a month.
That's coming to an end: The FDA declared the tirzepatide shortage over in December and did the same for the semaglutide shortage in February. Compounders must now pull their products. The grace period for tirzepatide manufacturers is over, and semaglutide producers have until Tuesday or May 22, depending on whether they're a state-licensed pharmacy or an outsourcing facility.
That leaves a huge opening for GLP-1 supplement sellers to flood the $49.3 billion global market — and convince consumers a $15 pack of unproven patches will yield the same results as brand-name drugs that have undergone comprehensive clinical trials, said Dr. W. Scott Butsch, director of obesity medicine at the Cleveland Clinic Bariatric and Metabolic Institute.
Butsch, who has previously consulted for Novo Nordisk (maker of Wegovy) and Eli Lilly (maker of Zepbound), said he was already concerned about the ubiquity of compounded semaglutide and tirzepatide in recent years.
'The FDA states very clearly: These compounded versions are not the same,' he said. 'They don't have the same ingredients. They have not been tested.'
Worse still, Butsch said, compounders and now supplement companies are using lower pricing to target an already vulnerable clientele. Walmart, for example, sells a variety of GLP-1 supplements under $50.
Blair Cromwell, the director of global communications for Walmart's U.S. Marketplace, said in a statement that dietary supplements are sold by third-party sellers on its Marketplace.
'Our policy allows the sale of dietary supplements if they comply with applicable regulations as well as federal, state and local laws, and FTC guidelines,' Cromwell said, adding that the company would be likely to review products marketed as GLP-1 supplements and 'remove them if found to make inappropriate or inaccurate claims.'
'[The wellness market] has continued to prey on the desperate, and these are people who have poor access,' Butsch said. 'Patients with obesity have always had poor access to obesity medications.'
He added, 'You have some optimism among people who think that they can save some money and still get the benefit. But it's a bigger carrot that they're carrying in front of the horse now.'
Dr. Dariush Mozaffarian, a cardiologist and the director of Tufts University's Food Is Medicine Institute, said, 'There's no simple dietary fix that's going to do what these drugs do in a short amount of time.'
Still, the metabolic mechanism the supplements claim to achieve — boosting natural GLP-1 production — isn't without merit.
'The food I'm eating is biologic information that's activating hormones in my body, including GLP-1,' Mozaffarian said, noting that healthy fats and high-fiber foods have been shown to trigger GLP-1 production. But its natural release into the bloodstream is fleeting; GLP-1 drugs work by mimicking the hormone and keeping it around longer, which can aid in appetite suppression.
'It's too early for [GLP-1 supplements] to have science behind them,' Mozaffarian said. 'But I do think in the future we will be able to give people more clear recommendations on what's a natural, lifestyle way to boost your GLP-1 function.'
For now, he said, 'I wouldn't spend money on these supplements, I would spend money on healthy food.'
Alan, of Michigan State University, was blunt.
'It's snake oil at this point,' she said. 'You're really wasting your money.'
This article was originally published on NBCNews.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cowboys Owner Jerry Jones Reveals Cancer Diagnosis, Credits Experimental Drug
Cowboys Owner Jerry Jones Reveals Cancer Diagnosis, Credits Experimental Drug

Fox Sports

timean hour ago

  • Fox Sports

Cowboys Owner Jerry Jones Reveals Cancer Diagnosis, Credits Experimental Drug

National Football League Cowboys Owner Jerry Jones Reveals Cancer Diagnosis, Credits Experimental Drug Published Aug. 13, 2025 5:53 p.m. ET share facebook x reddit link Dallas Cowboys owner Jerry Jones credited an experimental trial drug for successfully treating advanced melanoma as he disclosed his cancer diagnosis publicly for the first time. Jones revealed his illness in a documentary, "America's Team: The Gambler and His Cowboys," which will debut on Netflix next week. The 82-year-old Jones then told The Dallas Morning News how he was initially diagnosed in June 2010 and underwent two surgeries on his lung and two on his lymph nodes over the next 10 years after skin cancer cells metastasized to other parts of his body. "I was saved by a fabulous treatment and great doctors and a real miracle (drug) called PD-1 (therapy)," Jones said. "I went into trials for that PD-1, and it has been one of the great medicines. I now have no tumors." First-year Cowboys head coach Brian Schottenheimer described Jones' fight with cancer as an "amazing story" and praised him for going public. "I'm glad that Jerry shared it, just because I think it gives people hope," Schottenheimer said Wednesday. "It gives people the strength to say, 'OK,' you know, 'Hey, you can beat this.'" ADVERTISEMENT Schottenheimer, 51, used his last news conference of the Cowboys' nearly monthlong stay in Southern California to talk about his own cancer diagnosis. He underwent surgery in 2003 for thyroid cancer at the Mayo Clinic in Rochester, Minnesota. Then-Washington Commanders owner Dan Snyder helped arrange Schottenheimer's treatment two years after firing his father, Marty Schottenheimer, as head coach. Brian Schottenheimer was Washington's quarterbacks coach during the 2001 season, the same year Snyder himself was treated for thyroid cancer. "It doesn't discriminate against anybody," Schottenheimer said. "And mine was certainly less serious, but I was 28 when I was diagnosed with thyroid cancer. Nothing like Stage 4, nothing like what Jerry and other people have to go through. But you hear that word 'cancer,' and it scares the hell out of you." Reporting by The Associated Press. Want great stories delivered right to your inbox? Create or log in to your FOX Sports account, and follow leagues, teams and players to receive a personalized newsletter daily! FOLLOW Follow your favorites to personalize your FOX Sports experience National Football League Dallas Cowboys What did you think of this story? share

Hundreds of groups push back on Trump denying lawful immigrants access to Head Start, other programs
Hundreds of groups push back on Trump denying lawful immigrants access to Head Start, other programs

NBC News

timean hour ago

  • NBC News

Hundreds of groups push back on Trump denying lawful immigrants access to Head Start, other programs

The Trump administration's expanded ban on immigrants' access to social services, such as Head Start and Meals on Wheels, could have a 'devastating' impact on children of immigrants, including U.S. citizens, hundreds of opponents told the federal government Wednesday. A total of 372 organizations have coalesced to oppose the administration's decision to make more federally funded health and human service programs off-limits to immigrants with some form of permission to be in the country. The groups say the administration wrongly promotes the expanded restrictions as part of its efforts to target illegal immigration. The policy actually 'directly targets lawfully present immigrants' by turning early learning centers, community health centers and mental health and addiction treatment programs 'into immigration checkpoints' where providers would have to check a person's immigration status, according to the groups. 'Undocumented immigrants already are not eligible for most federally funded programs. This is another case where the administration is lying to the public,' said Adriana Cadena, director of the Protecting Immigration Families coalition, which led the organizations' opposition to restrictions to be implemented by the Department of Health and Human Services (HHS). As a result, the restrictions will harm millions, the groups stated in official comments filed in response to the administration's expanded restrictions, published in the Federal Register July 14. The deadline for public comment on the new restrictions was set for 11:59 p.m. Wednesday. One in 4 children in the U.S. are in a family with at least one immigrant parent. In 2023, 86% of those children were born in the U.S., making them U.S. citizens, according to Migration Policy Institute, an immigration think tank. (President Donald Trump also wants to change such birthright citizenship.) Even if a U.S. citizen child is entitled to use a program, the Trump administration's restrictions are likely to cause confusion and misunderstanding, Cadena said, because of the many children who are in families whose members have different types of immigration status. "This is going to have long-term consequences we cannot begin to grasp," she said. In response to an NBC News request for comment, the White House sent a link to a July 10 news release by HHS announcing the new restrictions. The administration said in the release that it was ensuring that public benefits were not 'diverted to subsidize illegal aliens.' 'For too long, the government has diverted hardworking Americans' tax dollars to incentivize illegal immigration,' HHS Secretary Robert F. Kennedy, Jr., stated in the July 10 release. 'Today's action changes that — it restores integrity to federal social programs, enforces the rule of law, and protects vital resources for the American people.' Expanding the programs restricted to 'qualified' immigrants The 1996 Personal Responsibility Reconciliation Act restricted the eligibility for federal public benefits to certain 'qualified' immigrants, according to KFF, a health policy group. Qualified immigrants have been defined as those lawfully present in the U.S. and do not include people with Temporary Protected Status, those who have Deferred Action for Childhood Arrivals (DACA) and others, KFF reported. The HHS has added 13 more programs to the list of programs open only to qualified immigrants. Those newly added by the administration include Head Start, some of the funding for community health centers, family planning services, child welfare prevention, kinship guardian assistance, substance abuse prevention, treatment and recovery and mental health services and the Community Services Block Grant, the groups said. The federal government has said the list is not comprehensive and more programs could be added later. The groups argue that the programs and immigrants' access to them have a larger benefit to society as a whole and that "reducing access to these vital programs will make all of our communities less healthy, less safe, less stable, less able to thrive." Restrictions on the HHS programs announced in July were to be effective immediately. Groups said little guidance has been given to providers regarding their implementation, creating confusion and having a chilling effect on people who are eligible for the programs and benefits as well as on the nonprofits, local governments and others who provide them. Several states have sued over the changes, which they said would also affect programs such as Meals on Wheels, domestic violence shelters, housing assistance and more. A lawsuit also was filed by the American Civil Liberties Union and others on behalf of parent groups challenging Trump's policies on Head Start. The administration provided a 30-day comment period for the new restrictions. "We do not necessarily expect that there is a real interest from the administration to seek comment on public policy that will impact millions of people," Cadena said. "This is all about the Trump administration's governmentwide attack on immigrant families, and to dismantle the safety net system that many Americans rely on," she said.

Novo Nordisk Rises 6% So Far in August: How to Play the Stock
Novo Nordisk Rises 6% So Far in August: How to Play the Stock

Yahoo

time2 hours ago

  • Yahoo

Novo Nordisk Rises 6% So Far in August: How to Play the Stock

Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating profit growth, resulting in a decline in its share price. The downgrade stems from weaker-than-expected momentum for its semaglutide-based obesity and diabetes drugs, Wegovy and Ozempic, especially in the U.S. obesity market. Despite the FDA ending its compounding grace period in May 2025, the company reported that illegal sales of counterfeit semaglutide persist under the pretext of personalization, hampering Wegovy's uptake. In response, the company is pursuing litigation and regulatory action to protect patients and market share. Wegovy's adoption has also been slower than anticipated in both cash and insured channels, despite efforts through NovoCare Pharmacy and telehealth partnerships. Market expansion has lagged, and competition in the GLP-1 obesity segment, especially from NVO's arch-rival, Eli Lilly LLY, has intensified. LLY markets its tirzepatide injections as Mounjaro for diabetes and Zepbound for obesity. Despite being on the market for a shorter duration, Lilly's Mounjaro and Zepbound have witnessed strong sales driven by rapid demand. Ozempic is also facing similar competitive pressures in the U.S. diabetes market, while international launches of Wegovy are experiencing uneven uptake across obesity markets. However, following a major pipeline setback for Eli Lilly, Novo Nordisk stock is staging a modest recovery, as is evident by the 5.8% gain in share price so far in August. Last week, LLY reported underwhelming efficacy results from the ATTAIN-1 study, the first of two pivotal phase III studies of its oral GLP-1 candidate, orforglipron, resulting in a significant drop in the stock price, given its strategic importance within Lilly's obesity pipeline. Investor sentiment was further dampened by the study's high patient discontinuation rates, stemming from both side effects and personal reasons, raising doubts about orforglipron's long-term utility in chronic obesity management. This presents a significant opportunity for Novo Nordisk to bounce back. NVO is making good progress with its pipeline, which includes several other new candidates for diabetes and obesity. The company also has strong fundamentals, and the untapped nature of the obesity market makes us believe that the stock has significant upside potential in the future. Let's dig deeper and understand the company's strengths and weaknesses to understand how to play the stock. Semaglutide – Still NVO's Primary Top-Line Driver Novo Nordisk's success in recent years has been driven by the sales of Ozempic (injection) and Rybelsus (oral) for diabetes, and Wegovy for obesity. Despite its recent market turmoil, the company holds a strong position in diabetes care, with one of the industry's broadest portfolios. Wegovy is a major revenue driver, recording sales of $5.41 billion (DKK 36.9 billion) during the first half of 2025, up 78% year over year on strong prescription growth. Ozempic also continues to boost overall revenues. To protect its lead amid competition from Lilly, Novo Nordisk is heavily investing in its GLP-1 manufacturing capacity. As of July 1, CVS Caremark, a major pharmacy benefit manager, has designated Wegovy as its preferred GLP-1 therapy for weight loss. Novo Nordisk is expanding semaglutide's reach through new indications. Wegovy is now approved for reducing major cardiovascular events, easing HFpEF symptoms, and relieving osteoarthritis-related knee pain in obesity. Ozempic's label includes use in diabetes patients with cardiovascular and kidney diseases. The FDA is reviewing Novo Nordisk's application for a 25 mg oral semaglutide for obesity, with a decision expected by year-end. Oral pills could boost adherence over injections. Potential approval would give Novo Nordisk a notable advantage as the sole manufacturer of a marketed oral obesity pill, positioning it to capture significant market share. NVO has also filed Rybelsus for cardiac event prevention in diabetes patients. A 7.2 mg Wegovy dose, showing up to 25% weight loss in the STEP UP study, is under EU review. Label expansion is also being sought for Ozempic in treating peripheral artery disease in the United States and the EU. Beyond its GLP-1 portfolio, Novo Nordisk is broadening its presence in rare diseases. The company is advancing regulatory plans for Mim8 in hemophilia A and has secured EU approval for Alhemo to treat hemophilia A and B with inhibitors. Alhemo is also under EU review for patients without inhibitors. In the United States, the therapy is already approved for both hemophilia A and B, with or without inhibitors. It also expects to file for semaglutide to treat metabolic dysfunction–associated steatohepatitis in both the United States and the EU in 2025. NVO Focuses on Next-Generation Drugs for Obesity Novo Nordisk is also developing several next-generation obesity candidates in its pipeline, especially targeting the lucrative U.S. market. The most advanced weight loss candidate in Novo Nordisk's pipeline is CagriSema, a fixed-dose combination of a long-acting amylin analogue and Wegovy. The company is planning its regulatory submission in 2026. Novo Nordisk is also developing a small-molecule oral CB1 inverse agonist, monlunabant, in a mid-stage study. The company is currently gearing up to advance Amycretin, an investigational unimolecular GLP-1 and amylin receptor agonist, for weight management into late-stage development. The phase III program on amycretin is planned to be initiated during the first quarter of 2026. Recently, Novo Nordisk signed a $2.2 billion deal with Septerna for developing and commercializing oral small-molecule medicines for treating obesity, diabetes and other cardiometabolic diseases. Competition Heating Up in the Obesity Space Competition in the obesity market is heating up as the obesity market is expected to expand to $100 billion by 2030, according to data from Goldman Sachs. Lilly and Novo Nordisk presently dominate the market. Several other companies, like Amgen AMGN and Viking Therapeutics VKTX, are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Amgen has begun a broad phase III program on its dual GIPR/GLP-1 receptor agonist, MariTide, across obesity, obesity-related conditions and diabetes, with the first two phase III studies initiated in March. Viking Therapeutics started two late-stage studies evaluating the subcutaneous formulation of its investigational obesity drug, VK2735. VKTX is also evaluating an oral version of this obesity drug in an ongoing mid-stage study, with a data readout expected later this year. NVO's Stock Price, Valuation, Estimates Year to date, Novo Nordisk shares have lost 42.1% compared with the industry's 8% decline. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below. The stock is currently trading below its 50 and 200-day moving averages. NVO Stock Underperforms the Industry, Sector & the S&P 500 Image Source: Zacks Investment Research Novo Nordisk is trading at a premium to the industry, as seen in the chart below. Going by the price/earnings ratio, the company's shares currently trade at 12.12 forward earnings, which is lower than 13.73 for the industry. The stock is trading much below its five-year mean of 29.25. NVO Stock Valuation Image Source: Zacks Investment Research Earnings estimates for 2025 have improved from $3.86 to $3.89 per share over the past seven days. During the same time frame, Novo Nordisk's 2026 earnings per share estimates have improved from $4.20 to $4.24. NVO Estimate Movement Image Source: Zacks Investment Research The stock's return on equity on a trailing 12-month basis is 78.64%, which is higher than 34.32% for the large drugmaker industry, as seen in the chart below. NVO Return on Equity Image Source: Zacks Investment Research Here's How to Play NVO Stock Novo Nordisk, currently carrying a Zacks Rank #3 (Hold), remains a strong long-term player in diabetes and obesity care despite recent guidance cuts and competitive pressures. The company holds a dominant GLP-1 market position, with Wegovy and Ozempic delivering strong double-digit sales growth and benefiting from expanding indications. A potential FDA approval for 25 mg oral semaglutide for obesity by year-end could give NVO a first-to-market edge, improving adherence and broadening its reach. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Competition from Eli Lilly remains intense, but Lilly's recent setback with oral candidate orforglipron has pivoted investor sentiment toward NVO. The company's deep pipeline, including next-generation obesity candidates like CagriSema and Amycretin, along with rare disease therapies such as Mim8 and Alhemo, offers broad potential for market expansion. Manufacturing expansions and strategic deals, including a $2.2 billion Septerna partnership, also support long-term growth. Given these strengths, current holders may retain their positions, while long-term investors could use the current price as an entry point. Near-term volatility is likely due to competition, uneven Wegovy uptake internationally, and legal action over counterfeit semaglutide, making it less attractive for short-term trading. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store